title: Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation.
abstract: BACKGROUND
  The impact of ABO incompatibility on hematopoietic stem cell transplantation (HSCT) outcome is controversial. As ABH substances are expressed on tissues and secreted in body fluids, they could drive an immune response in minor ABO-incompatible HSCT. The aim of the study was to investigate the prognostic role of the recipients' ABH secretor status.
  
  
  METHODS
  Patients who underwent minor ABO-incompatible HSCT were included. Secretor status was determined either serologically or by molecular genetics.
  
  
  RESULTS
  Between March 1996 and June 2012, a total of 176 patients received minor ABO-incompatible HSCT and 150 (85%) were secretors. Incidence and severity of acute graft-versus-host disease (GVHD) and chronic GVHD did not differ between secretors and nonsecretors (cumulative incidences ± standard errors: acute GVHD on Day 100, 41 ± 11 and 46 ± 5%, p = 0.59; chronic GVHD at 2 years, 52 ± 13 and 56 ± 5%, p = 0.62, for secretors and nonsecretors, respectively). Additionally, nonrelapse mortality (NRM) and overall survival (OS) were similar in the two groups (2-year NRM, 27 ± 9 and 23 ± 3%, p = 0.45; 4-year OS, 64 ± 10 and 55 ± 4%, p = 0.28, for secretors and nonsecretors, respectively).
  
  
  CONCLUSIONS
  The recipients' ABH secretor status in minor ABO-incompatible HSCT has no prognostic impact on major transplant outcomes.
authors.affiliation: Division of Hematology, University Hospital, Basel, Switzerland; Blood Transfusion Centre, Swiss Red Cross, Basel, Switzerland.
authors.forename: Andreas
authors.initials: A
authors.lastname: Holbro
authors.forename: Martin
authors.initials: M
authors.lastname: Stern
authors.forename: Laura
authors.initials: L
authors.lastname: Infanti
authors.forename: Alix
authors.initials: A
authors.lastname: O'Meara
authors.forename: Beatrice
authors.initials: B
authors.lastname: Drexler
authors.forename: Beat M
authors.initials: BM
authors.lastname: Frey
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Tiercy
authors.forename: Jakob R
authors.initials: JR
authors.lastname: Passweg
authors.forename: Christoph
authors.initials: C
authors.lastname: Gassner
authors.forename: Andreas
authors.initials: A
authors.lastname: Buser
authors.forename: Joerg-Peter
authors.initials: JP
authors.lastname: Sigle
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000328:Adult; D064591:Allografts; D001787:Blood Group Incompatibility / Q000235:genetics / Q000276:immunology*; D005260:Female; D005647:Fucosyltransferases / Q000235:genetics*; D005838:Genotype; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000235:genetics / Q000276:immunology; D006402:Hematologic Diseases / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D007983:Lewis Blood Group Antigens / Q000235:genetics; D019520:Living Donors; D008297:Male; D010641:Phenotype; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D000097631:Galactoside 2-alpha-L-fucosyltransferase
chemical_list: D000017:ABO Blood-Group System; D005647:Fucosyltransferases; D007983:Lewis Blood Group Antigens; D000097631:Galactoside 2-alpha-L-fucosyltransferase; C031692:galactoside 3-fucosyltransferase